Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis

Fig. 3

Neoadjuvant therapy in patients with lung cancer network meta-analysis of efficacy and safety. (a) : PCR (b) : MPR (c) : EFS (d) : Rates of undergoing surgery (e) : Grade ≥ 3 AEs. (f) : R0 resection rate. (A) Hazard ratios and 95% CIs for Event-free survival(EFS), and a hazard ratio < 1.00 provides better survival benefits. (B) ORs and 95% CIs for Pathological complete response(PCR), Major Pathological response(MPR), Rates of undergoing surgery and R0 resection rate, and an OR>1.00 indicates a better efficacy. ORs and 95% CIs for Grade ≥ 3 AEs, and an OR < 1.00 indicates a better efficacy. CT: chemotherapy; Nivo-CT: nivolumab plus chemotherapy, Tori-CT: Toripalimab plus chemotherapy; Durv-CT: duvalumab plus chemotherapy, Pemb-CT: pembrolizumab plus chemotherapy; Tis-CT: Tislelizumab plus chemotherapy; Ipi + Nivo-CT: ipilimumab plus nivolumab plus chemotherapy

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us